Both

OFC and check details quetiapine have shown clear superiority over placebo and are reasonable first-choice agents. Of atypical antipsychotics, the data most, strongly support, quetiapine in the treatment of bipolar depression, with widespread effects across the core symptoms of depression, including an ability to reduce suicidal thinking.33 When patients are nonresponsive or only partially responsive to a trial of a single mood stabilizer, considerations include switching to an alternate mood stabilizer/atypical antipsychotic, combining mood Inhibitors,research,lifescience,medical stabilizers/atypical antipsychotics, or augmenting with an agent that may possess clinical, but often less empirical evidence, to support its use. Among mood stabilizers, lithium, lamotrigine, and divalproex should be given initial consideration, while among atypical antipsychotics, only olanzapine and quetiapine are substantiated by trialbased assessments. Of moderately sized, multicenter studies, only lamotrigine24 and modafinil56 Inhibitors,research,lifescience,medical have been

shown to reduce depression more effectively than placebo when administered adjunctively to a mood stabilizer. For all agents, it should be kept, in mind that an adequate trial consists of at Inhibitors,research,lifescience,medical least 6 weeks of treatment. Over the last decade, we clinicians have witnessed tremendous advances in our ability to manage the depressed phase of bipolar disorder. Nevertheless, even with access to the most, novel pharmacological compounds and adherence to research-driven treatment algorithms, bipolar Inhibitors,research,lifescience,medical disorder remains a burdensome and chronic illness. In as much, less than one third of patients who achieve recovery are likely to remain well over 2 years of follow-up.13 These sobering outcomes invite the need for clinical trials seeking to prevent depressive relapse and to explore whether combination treatments provide added efficacy, increased effectiveness, and enhanced recovery. Such trials might employ sequential, adaptive design schemes that incorporate advances

in our understanding of Inhibitors,research,lifescience,medical genomics and the neurobiological underpinnings of bipolar disorder. It is the expectation that the next generation of clinical trials will provide more personalized and predictive treatment options for those who Terminal deoxynucleotidyl transferase suffer from this protean disorder. Selected abbreviations and acronyms 5-HT serotonin BOLDER Bipolar Depression Studies (quetiapine) BP bipolar disorder CGI Clinical Global Impressions MADRS Montgomery-Asberg Depression Rating Scale OFC olanzapine-fluoxetine combination STEP-BD Systematic Treatment Enhancement Program for Bipolar Disorder Notes Dr Kemp has acted as a consultant for Abbott, Bristol-Myers Squibb, and Wyeth; has received an honorarium from Servier; has participated in CME activities by Organon a part of Schering-Plough; and has received research support from the National Institutes of Health and Takeda.